GBI Research, the leading business intelligence provider, has released its latest research, “Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth”, which provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline.

1. Adult and Adolescent Vaccines Market to 2017 – Accelerated Development and
Introduction Plans (ADIP) by GAVI Alliance to Drive Growth
ReportsnReports.com adds GBI Research Market Research Report “Adult and Adolescent
Vaccines Market to 2017 – Accelerated Development and Introduction Plans (ADIP) by GAVI
Alliance to Drive Growth‟‟ to its store.
GBI Research, the leading business intelligence provider, has released its latest research,
“Adult and Adolescent Vaccines Market to 2017 – Accelerated Development and Introduction
Plans (ADIP) by GAVI Alliance to Drive Growth”, which provides insights into the global
vaccines market, forecast until 2017. The report provides an in-depth analysis of five
vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and
hepatitis B. The report also examines the immunization schedules for the covered vaccines.
In addition, the report also includes insights into the vaccines R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary
and secondary research, and in-house analysis by GBI Research‟s team of industry experts.
GBI Research‟s analysis shows that the overall global vaccines market was valued at $28
billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the
forecast period, and will reach $56.7 billion by 2017. The global market revenues are
expected to increase due to the introduction of new molecules which are currently in the
regulatory filing stage, and those in the later stages of development. The top
pharmaceutical companies in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer,
Novartis AG., Merck & Co. Inc, and SP-MSD. Approximately 88% of the market is covered
by these six companies.
Scope
The scope of this report includes -
 Data and analysis on the global adult and adolescent vaccines market
 Annualized market data for the adult and adolescent vaccines market from 2007 to
2017 for pneumococcal vaccines, human pappilomavirus vaccines, seasonal flu
vaccines, hepatitis A vaccines and hepatitis B vaccines
 Key drivers and restraints that have had a significant impact on the market

2.  The competitive landscape of the global vaccines market
 Key M&A activities, licensing agreements and co-development deals that took place in
the vaccines market between 2009 and 2011.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
 Align your product portfolio to the markets with high growth potential.
 Develop market-entry and market expansion strategies by identifying the potential
region and therapeutic segments poised for strong growth.
 Devise a more tailored country strategy through the understanding of key drivers and
barriers of the vaccines market.
 Develop key strategic initiatives by understanding the key focus areas and leading
companies.
 Accelerate and strengthen your market position by identifying key companies for
mergers, acquisitions and strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 9
2 Adult and Adolescent Vaccines Market to 2017: Introduction 11
2.1 Overview 11
2.2 GBI Research Report Guidance 12
3 Adult and Adolescent Vaccines Market to 2017: Market Overview 13
3.1 Vaccine Preventable Diseases 13
3.2 Vaccine Manufacturing Process 14
4 Adult and Adolescent Vaccines Market to 2017: Global Vaccines Market 15
4.1 Market Forecasts 15
4.2 Market Share by Diseases Sector 17
4.3 Market Share by Geography 18
4.4 Average Cost of Vaccination per Child 19

3. 4.5 Target Population 19
4.6 Immunization Coverage 22
4.7 Unmet Needs 24
4.8 Market Trends 25
4.8.1 Immunization Programs 25
4.8.2 Public Private Partnerships 25
4.8.3 Production Capacity 26
4.8.4 Reimbursements 26
4.9 Drivers 26
4.9.1 Growth will be Driven by Vaccines Targeting New Diseases 27
4.9.2 The Adult Vaccines Segment will Provide a Significant Boost to Growth of the Market
27
4.9.3 Pediatric Combination Vaccines will Continue to Drive Growth 27
4.9.4 Availability of Vaccine Technologies That Help Increase Efficacy and Safety will Drive
Innovation and Growth 27
4.9.5 Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future 27
4.10 Barriers 28
4.10.1 Limitations in Production Capacity Delay the Realization of Potential 28
4.10.2 High Initial Capital Investments and Technical Expertise Act as Entry Barriers 28
4.10.3 Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance 28
5 Adult and Adolescent Vaccines Market to 2017: The US Vaccines Market 29
5.1 Market Overview 29
5.2 Market Forecasts 29
5.3 Cost of Vaccination per Child in the US 31
5.4 Immunization Schedule 32
5.5 Regulatory Framework 33
5.6 Vaccine Procurement 34
5.7 Vaccine Stockpiling 35
6 Adult and Adolescent Vaccines Market to 2017: European Vaccines Market 36
6.1 Market Overview 36
6.2 Market Forecasts 36
6.3 Average Cost of Vaccination per Child 38
6.4 Vaccine Stockpiling 38
6.5 The UK 39

4. 6.5.1 Immunization Schedule 39
6.5.2 Regulatory Framework 39
6.5.3 Vaccine Procurement 39
6.6 France 40
6.6.1 Immunization Schedule 40
6.6.2 Regulatory Framework 41
6.6.3 Vaccine Procurement 41
6.7 Germany 42
6.7.1 Immunization Schedule 42
6.7.2 Regulatory Framework 43
6.7.3 Vaccine Procurement 44
6.8 Italy 44
6.8.1 Immunization Schedule 44
6.8.2 Regulatory Framework 44
6.8.3 Vaccine Procurement 45
6.9 Spain 45
6.9.1 Immunization Schedule 45
6.9.2 Regulatory Framework 46
6.9.3 Vaccine Procurement 47
7 Adult and Adolescent Vaccines Market to 2017: Rest of the World Vaccines
Market 48
7.1 Market Overview 48
7.2 Market Forecasts 48
7.3 Average Cost of Vaccination per Child 49
7.4 Immunization Schedule 49
7.5 Regulatory Framework 49
7.6 Vaccine Procurement 49
7.7 Vaccine Stockpiling 50
8 Adult and Adolescent Vaccines Market to 2017: Pneumococcal Vaccines Market
51
8.1 Market Overview 51
8.2 Market Forecasts 51
8.3 Average Cost of Vaccination 52
8.4 Target Population 53

5. 8.5 Immunization Coverage 54
8.6 Product Analysis 54
8.6.1 Prevnar 7 54
8.6.2 Prevnar 13 (pneumococcal 13-valent conjugate vaccine) 54
8.6.3 Pneumovax 23 55
8.6.4 Synflorix 56
8.7 Vaccine Pipeline Analysis 57
8.7.1 Phase lll 57
8.7.2 Phase ll 58
8.7.3 Phase l 58
8.7.4 Preclinical/Discovery 58
9 Adult and Adolescent Vaccines Market to 2017: Human Pappilomavirus Vaccines
Market 59
9.1 Market Overview 59
9.2 Market Forecasts 59
9.3 Average Cost of Vaccination 60
9.4 Target Population 61
9.5 Immunization Coverage 62
9.6 Product Analysis 62
9.6.1 Gardasil 62
9.6.2 Cervarix 63
9.7 Vaccine Pipeline Analysis 63
9.7.1 Phase lll 63
9.7.2 Phase ll 64
9.7.3 Phase l 65
9.7.4 Preclinical/Discovery 66
10 Adult and Adolescent Vaccines Market to 2017: Seasonal Flu Vaccines Market
67
10.1 Market Overview 67
10.2 Average Cost of Vaccination 71
10.3 Target Population 72
10.4 Immunization Coverage 73
10.5 Product Analysis 73
10.5.1 Fluzone 73

6. 10.5.2 Fluarix 73
10.6 Vaccine Pipeline Analysis 74
10.6.1 Regulatory Filed Products 74
10.6.2 Phase lll 74
10.6.3 Phase ll 75
10.6.4 Phase l 76
10.6.5 Preclinical/Discovery 77
11 Adult and Adolescent Vaccines Market to 2017: Hepatitis A Vaccines Market 79
11.1 Market Overview 79
11.2 Market Forecasts 79
11.3 Average Cost of Vaccination 80
11.4 Target Population 81
11.5 Product Analysis 82
11.5.1 Twinrix 82
11.5.2 Havrix 83
11.5.3 Vaqta 83
11.5.4 Ambirix 84
11.5.5 Avaxim 84
11.6 Vaccine Pipeline Analysis 85
11.6.1 NDA Filed Molecules 85
11.6.2 Phase lll 85
11.6.3 Preclinical/Discovery 85
12 Adult and Adolescent Vaccines Market to 2017: Hepatitis B Vaccines Market 86
12.1 Market Overview 86
12.2 Market Forecasts 87
12.3 Average Cost of Vaccination 88
12.4 Target Population 89
12.5 Product Analysis 90
12.5.1 Recombivax HB 90
12.5.2 Engerix-B 90
12.5.3 Twinrix 91
12.5.4 Comvax 91
12.6 Vaccine Pipeline Analysis 91
12.6.1 Regulatory Filed Products 91

7. 12.6.2 Phase lll 92
12.6.3 Phase ll 93
12.6.4 Phase l 93
12.6.5 Preclinical/Discovery 94
13 Adult and Adolescent Vaccines Market to 2017: Competitive Landscape 95
13.1 Overview 95
13.2 Market Share Analysis 96
14 Adult and Adolescent Vaccines Market to 2017: Strategic Consolidations 98
14.1 Mergers & Acquisitions 98
14.1.1 Overview 98
14.1.2 Top Deals in M&A 98
14.1.3 M&A by Indication 99
14.1.4 M&A by Year 100
14.1.5 M&A by Geography 101
14.1.6 M&A by Value 102
14.2 Licensing Agreements 103
14.2.1 Overview 103
14.2.2 Top Licensing Deals 103
14.2.3 Licensing Deals by Indication 104
14.2.4 Licensing Deals by Year 105
14.2.5 Licensing Deals by Geography 106
14.2.6 Licensing Deals by Value 107
14.3 Co-Development Deals 108
14.3.1 Overview 108
14.3.2 Top Co-Development Deals 108
14.3.3 Co-Development Deals by Indication 109
14.3.4 Co-Development Deals by Year 110
14.3.5 Co-Development Deals by Geography 111
14.3.6 Co-Development Deals by Value 112
15 Appendix 113
15.1 Market Definitions 113
15.2 Abbreviations 113
15.3 Research Methodology 114

8. 15.4 Global Vaccines Market 114
15.4.1 Coverage 114
15.4.2 Sources of Coverage 115
15.4.3 Methodology 115
15.5 Geographical Landscape 115
15.5.1 Coverage 115
15.5.2 Sources of Coverage 115
15.5.3 Methodology 115
15.6 Market Characterization 116
15.6.1 Coverage 116
15.6.2 Sources of Coverage 116
15.6.3 Methodology 116
15.7 Competitive Landscape 116
15.7.1 Coverage 116
15.7.2 Sources of Coverage 116
15.7.3 Methodology 117
15.8 Pipeline Analysis 117
15.8.1 Coverage 117
15.8.2 Sources of Coverage 117
15.8.3 Methodology 117
15.9 Strategic Consolidations 117
15.9.1 Coverage 117
15.9.2 Sources of Coverage 117
15.9.3 Methodology 117
15.10 Contact Us 117
15.11 Disclaimer 118
15.12 Sources 118
1.1 List of Tables
Table 1: Adult and Adolescent Vaccines Market to 2017, Vaccine Preventable Disease, 2010
13
Table 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-
2017 15
Table 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication
(%), 2010 17
Table 4: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population

9. („000), 2007-2017 20
Table 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population
(„000), 2007-2017 21
Table 6: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage
(%), 2007-2009 23
Table 7: Adult and Adolescent Vaccines Market to 2017, Global, GAVI Achievements, 2008-
2010 25
Table 8: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-
2017 29
Table 9: Adult and Adolescent Vaccines Market to 2017, the US, Cost of Vaccination ($),
2010 31
Table 10: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-
2017 37
Table 11: Adult and Adolescent Vaccines Market to 2017, Europe, Average Cost of
Vaccination ($), 2009 38
Table 12: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues
($bn), 2007-2017 48
Table 13: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues
($bn), 2007-2017 51
Table 14: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Annual
Cost of Vaccination ($), 2007-2017 52
Table 15: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Target
Population („000), 2007-2017 53
Table 16: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase lll
Molecules, 2011 57
Table 17: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase ll
Molecules, 2011 58
Table 18: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase l
Molecules, 2011 58
Table 19: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Preclinical
/ Discovery Molecules, 2011 58
Table 20: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn),
2007-2017 59
Table 21: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost of
Vaccination ($), 2007-2017 60
Table 22: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population

10. („000), 2007-2017 61
Table 23: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Product Comparison,
2007-2017 62
Table 24: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase lll Molecules,
2011 63
Table 25: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase ll Molecules,
2011 64
Table 26: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase l Molecules,
2011 65
Table 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Preclinical /
Discovery Molecules, 2011 66
Table 28: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues
($bn), 2007-2017 69
Table 29: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual Cost
of Vaccination ($), 2007-2017 71
Table 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Target
Population („000), 2007-2017 72
Table 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Regulatory
Filed Molecules, 2011 74
Table 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase lll
Molecules, 2011 74
Table 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase ll
Molecules, 2011 75
Table 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase l
Molecules, 2011 76
Table 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Preclinical /
Discovery Molecules, 2011 77
Table 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues
($m), 2007-2017 79
Table 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Cost
of Vaccination ($), 2007-2017 80
Table 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Target
Population (million), 2007-2017 81
Table 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, NDA Filed
Molecules, 2011 85
Table 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Phase lll

11. Molecules, 2011 85
Table 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Preclinical /
Discovery Molecules, 2011 85
Table 42: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues
($m), 2007-2017 87
Table 43: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Cost
of Vaccination ($), 2007-2017 88
Table 44: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Target
Population (million), 2007-2017 89
Table 45: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Regulatory
Filed Molecules, 2011 91
Table 46: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase lll
Molecules, 2011 92
Table 47: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase ll
Molecules, 2011 93
Table 48: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase l
Molecules, 2011 93
Table 49: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Preclinical /
Discovery Molecules, 2011 94
Table 50: Adult and Adolescent Vaccines Market to 2017, Global, Top Deals in M&A (%),
2009-2011 98
Table 51: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-
2011 99
Table 52: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011 100
Table 53: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-
2011 101
Table 54: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011
102
Table 55: Adult and Adolescent Vaccines Market to 2017, Global, Top Licensing Deals ($m),
2009-2011 103
Table 56: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication (%),
2009-2011 104
Table 57: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%),
2009-2011 105
Table 58: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography
(%), 2009-2011 106

12. Table 59: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%),
2009-2011 107
Table 60: Adult and Adolescent Vaccines Market to 2017, Global, Co-Development Deals,
2009-2011 108
Table 61: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by
Indication (%), 2009-2011 109
Table 62: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year
(%), 2009-2011 110
Table 63: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by
Geography (%), 2009-2011 111
Table 64: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value
(%), 2009-2011 112
1.2 List of Figures
Figure 1: Adult and Adolescent Vaccines Market to 2017, Global, Vaccine Manufacturing
Process, 2010 14
Figure 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-
2017 15
Figure 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication
(%), 2010 17
Figure 4: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By
Geography (%), 2010 18
Figure 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population
(„000), 2007-2017 19
Figure 6: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population
(„000), 2007-2017 20
Figure 7: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage
(%), 2007-2009 22
Figure 8: Adult and Adolescent Vaccines Market to 2017, Global, Unmet Need, 2010 24
Figure 9: Adult and Adolescent Vaccines Market to 2017, Global, Drivers and Barriers, 2007-
2017 26
Figure 10: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-
2017 29
Figure 11: Adult and Adolescent Vaccines Market to 2017, the US, Immunization Schedule,
2010 32
Figure 12: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Development and

13. Approval Process, 2010 33
Figure 13: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Procurement,
2010 34
Figure 14: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-
2017 36
Figure 15: Adult and Adolescent Vaccines Market to 2017, the UK, Immunization Schedule,
2010 39
Figure 16: Adult and Adolescent Vaccines Market to 2017, France, Immunization Schedule,
2010 40
Figure 17: Adult and Adolescent Vaccines Market to 2017, France, Distribution of Vaccine
Administration by Sector, 2010 41
Figure 18: Adult and Adolescent Vaccines Market to 2017, Germany, Immunization
Schedule, 2010 42
Figure 19: Adult and Adolescent Vaccines Market to 2017, Germany, Distribution of Vaccine
Administration by Sector, 2010 43
Figure 20: Adult and Adolescent Vaccines Market to 2017, Italy, Immunization Schedule,
2010 44
Figure 21: Adult and Adolescent Vaccines Market to 2017, Spain, Immunization Schedule,
2010 45
Figure 22: Adult and Adolescent Vaccines Market to 2017, Spain, Distribution of Vaccine
Administration by Sector, 2010 46
Figure 23: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues
($bn), 2007-2017 48
Figure 24: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues
($bn), 2007-2017 51
Figure 25: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Annual
Cost of Vaccination ($), 2007-2017 52
Figure 26: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Target
Population („000), 2007-2017 53
Figure 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn),
2007-2017 59
Figure 28: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost of
Vaccination ($), 2007-2017 60
Figure 29: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population
(„000), 2007-2017 61
Figure 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Number of

14. Doses Produced, 2000-2010 67
Figure 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Sales by
Channel (%), 2009 68
Figure 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Vaccines
Produced by Manufacturer, 2009-2010 68
Figure 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues
($bn), 2007-2017 69
Figure 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual
Cost of Vaccination ($), 2007-2017 71
Figure 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Target
Population („000), 2007-2017 72
Figure 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues
($m), 2007-2017 79
Figure 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Cost
of Vaccination ($), 2007-2017 80
Figure 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Target
Population (million), 2007-2017 81
Figure 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues
($m), 2007-2017 87
Figure 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Cost
of Vaccination ($), 2007-2017 88
Figure 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Target
Population (million), 2007-2017 89
Figure 42: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 2009
96
Figure 43: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 2010
97
Figure 44: Adult and Adolescent Vaccines Market to 2017, Strategic Consolidations (%),
2009-2011 98
Figure 45: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-
2011 99
Figure 46: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011
100
Figure 47: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-
2011 101
Figure 48: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011

15. 102
Figure 49: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication
(%), 2009-2011 104
Figure 50: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%),
2009-2011 105
Figure 51: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography
(%), 2009-2011 106
Figure 52: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%),
2009-2011 107
Figure 53: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by
Indication (%), 2009-2011 109
Figure 54: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year
(%), 2009-2011 110
Figure 55: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by
Geography (%), 2009-2011 111
Figure 56: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value
(%), 2009-2011 112
Latest Market Research Reports:
 Radiation Detection Materials Markets – 2011
 Printed Battery Markets – 2011
 Global MDI, TDI and Polyurethane Market by Type, Applications, Prices, Regulations
Trends & Forecasts 2011-2016
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

16. Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Market Research Blog